化学
克拉斯
咪唑
激酶
IC50型
立体化学
体外
癌症研究
药理学
生物化学
突变
生物
基因
作者
Peng Wang,Yongting Yuan,Tao Yang,Yurong Zou,Minghai Tang,Ziyan Ma,Weichen Bo,Songhui Qin,Yong Xia Chen,Tao Guo,Zhongning Guo,Jianhong Yang,Mingli Xiang,Lijuan Chen
标识
DOI:10.1021/acs.jmedchem.4c00860
摘要
Herein, we described the rational drug design and synthesis of a series of 5-amino-4-fluoro-1 H -benzo[ d ]imidazole-6-carboxamide derivatives that inhibit MEK and RAF kinases. The detailed screening cascades revealed that 16b was a preferred compound, which might act like a “clamp” to stabilize the MEK/RAF complex, thereby effectively inhibiting MEK1, BRAF, and BRAF V600E with IC 50 values of 28, 3, and 3 nM, respectively. 16b possessed an excellent selectivity over other 312 human-related kinases at 1 μM. In vitro, 16b showed potent antiproliferative activities against MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells with IC 50 values of 0.011, 0.079, and 0.096 μM, respectively. CoIP experiments demonstrated that 16b could induce MEK/RAF complex formation. Most importantly, in the C26 syngeneic colorectal and HCT116 mice xenograft tumor models, 16b demonstrated tumor growth inhibition of 70 and 93%, respectively, suggesting that 16b may be a promising MEK/RAF complex inhibitor and worthy of further development.
科研通智能强力驱动
Strongly Powered by AbleSci AI